Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
December 21, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on...
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
December 13, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update
November 15, 2021 08:00 ET
|
Galectin Therapeutics Inc.
Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning...
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
November 05, 2021 16:24 ET
|
Galectin Therapeutics Inc.
New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis:...
Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Treatment of Checkpoint-Refractory Advanced Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
October 28, 2021 06:00 ET
|
Provectus Biopharmaceuticals Inc.
34.1 months median overall survival, 4.9 months median progression-free survivalBest overall response (RECIST 1.1): 5% CR, 26% ORR, 53% DCR (19 patients) KNOXVILLE, TN, Oct. 28, 2021 (GLOBE...
Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
October 27, 2021 08:00 ET
|
Galectin Therapeutics Inc.
New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis:...
UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
October 05, 2021 15:39 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein
September 21, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered...
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
September 16, 2021 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s...